Diversified healthcare company CVS Health (NYSE:CVS) announced in Q1 CY2025, with sales up 7% year on year to $94.59 billion.

CVS Health CVS shares have rallied nearly 38% so far this month, driven by the company’s stronger-than-expected first-quarter ...

India's commercial vehicle (CV) sales aim to cross 1 million units in FY26 after two slow years. Improved freight rates, ...

CVS Health (CVS) stock in focus as Glenview Capital trims a third of its stake after the company's Q1 2025 earnings beat.

EBITDA and Adjusted EBITDA as presented in this release are supplemental measures of our performance that are neither required by, nor presented in accordance with, GAAP. EBITDA and Adjusted EBITDA ...

CVS Health has raised its full-year profit forecast, driven by robust performance across its sectors and strategic ... CVS anticipates improved financial health amid growing healthcare demands from ...

The updated guidance is detailed in the following slide: CVS Health’s first quarter results demonstrate the company’s ability to execute on its strategic priorities while delivering strong financial ...

Following the earnings release, CVS Health’s stock surged 8.8% in premarket trading, reflecting investor confidence in the company’s strategic direction and financial performance. According to ...

CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be ...

CVS Health President and CEO. The company’s Health Care Benefits segment saw adjusted operating income surge to $1.99 billion from $732 million a year ago, driven by favorable prior-year development ...

(Reuters) -Eli Lilly on Thursday downplayed CVS Health (NYSE:CVS)’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of ...